|
Jul 31
|
Renal Failure Clinical Trials Market Landscape Report 2025 Featuring Bayer, AstraZeneca, Amgen, Sanofi, Novartis, AbbVie, Roche, Pfizer, Takeda, Astellas
|
|
Jul 31
|
Multiple Sclerosis Clinical Trials Market Landscape Report 2025 Featuring Biogen, Novartis, Sanofi, Merck, Teva, Bayer, Roche, Bristol-Myers Squibb, Laboratory Corp of America, IQVIA
|
|
Jul 30
|
NuCicer Raises $11.5M to Scale High-Protein Chickpeas and Accelerate Predictive Breeding Platform
|
|
Jul 30
|
Merz Aesthetics Strengthens U.S. Commercial Leadership With Key Executive Hires
|
|
Jul 29
|
INCY's Q2 Earnings & Revenues Beat Estimates on Higher Product Sales
|
|
Jul 29
|
Chondrosarcoma Market Report 2025-2035: Increased Research on Rare Skeletal Tumors and IDH1/2 Mutation-targeted Therapies
|
|
Jul 25
|
Bayer Provides Regulatory Update on Elinzanetant for the Treatment of Moderate to Severe Hot Flashes Due to Menopause
|
|
Jul 24
|
Do Q2 Reports Shape a More Uncertain Outlook?
|
|
Jul 24
|
Europe Pyridine Industry Analysis Report 2025-2033 | Germany and France Lead with Strong Agricultural and Pharmaceutical Sectors, Green Chemistry Drive Usage in the UK amidst Post-Brexit Adjustments
|
|
Jul 24
|
Mountain Valley MD Holdings Announces Changes to Board of Directors
|
|
Jul 22
|
SRPT Slides on Voluntary US Elevidys Shipment Pause Amid Scrutiny
|
|
Jul 22
|
Certified Organic Agricultural Inputs Trends Analysis Report 2025 | Market to Reach $14.36 Billion by 2032, Emerging Markets in Developing Regions Fueling Opportunities
|
|
Jul 22
|
Best Value Stocks to Buy for July 22nd
|
|
Jul 22
|
New Strong Buy Stocks for July 22nd
|
|
Jul 21
|
SRPT Down After Third Death in Muscular Dystrophy Gene Therapy Program
|
|
Jul 21
|
VTRS Down on Late-Stage Study Failure of Eye Disease Drug
|
|
Jul 21
|
Europe RNAi Pesticides Market Research Report 2024-2034 | Strategic Collaborations Propel Innovations, Growing Emphasis on Lowering Dependency on Traditional Chemical Pesticides
|
|
Jul 21
|
Darolutamide receives EU approval in third indication for patients with advanced prostate cancer
|
|
Jul 18
|
Regeneron Stock Plunges 22.6% YTD: Should You Buy, Sell or Hold?
|
|
Jul 17
|
MDGL Stock Soars 11% on New Patent Protecting Rezdiffra Dosing Rights
|